What will be the reduction in DUX4 regulated genes in the next AOC 1020 trial update by March 31, 2025? | Categorical | | | 7 months ago | |
Will Avidity Biosciences' stock price increase by 50% from June 12, 2024, by end of 2024? | Binary | | | 7 months ago | |
Will AOC 1020 receive FDA approval for FSHD treatment by June 30, 2025? | Binary | | | 7 months ago | |
Will Avidity Biosciences move AOC 1020 to Phase 3 trials by end of 2024? | Binary | | | 7 months ago | |
Avidity Biosciences stock price at year-end 2024 | Categorical | | | 7 months ago | |
AOC 1020 achieves primary endpoint in FORTITUDE Phase 1/2 trial? | Binary | | | 7 months ago | |
Avidity Biosciences receives FDA Fast Track designation for AOC 1020? | Binary | | | 7 months ago | |
Avidity Biosciences partners with a major pharmaceutical company for AOC 1020? | Binary | | | 7 months ago | |
Which drug will show higher efficacy in treating FSHD by end of 2024? | Categorical | | | 7 months ago | |
Which company will have a larger market share in FSHD treatments by end of 2024? | Categorical | | | 7 months ago | |
Percentage reduction in DUX4 regulated genes in FORTITUDE Phase 1/2 trial | Categorical | | | 7 months ago | |
Number of patients showing functional improvement in FORTITUDE Phase 1/2 trial | Categorical | | | 7 months ago | |
